SR-17018

SR-17018 as an informal taper tool — what it is, the community protocol, real risks, what's unknown.

⚠️ Community information, not medical advice. SR-17018 is a research chemical not approved for human use anywhere in the world. The information below reflects community experience, published research on rodent models, and harm reduction principles. **For discussion, see #sr17018 **

SR-17018 is a synthetic compound originally developed at the Scripps Research Institute and first described in scientific literature by Laura Bohn and colleagues in 2017. It’s a biased mu-opioid receptor agonist with a pharmacological profile that’s genuinely different from classical opioids like morphine, oxycodone, or even buprenorphine, and that profile has made it interesting to people trying to come off opioid dependence.

On Reddit and other forums, discussion of SR-17018 dramatically increased through 2024, with the compound emerging as an informal tool for opioid discontinuation and withdrawal management. Some people in this community have used it as part of their plan to come off 7-OH and the related synthetics. It’s a valid option worth understanding. It’s also still an opioid, and we want to be honest about that.

What makes it pharmacologically interesting

SR-17018 is a biased partial agonist at the mu-opioid receptor with strong selectivity for activation of G protein signaling over β-arrestin2 recruitment. The G-protein-vs-β-arrestin distinction matters because the analgesic and reward effects of opioids run primarily through G-protein signaling, while many of the worst side effects (respiratory depression, severe withdrawal, fast tolerance buildup) involve β-arrestin signaling. Compounds biased toward G-protein signaling theoretically deliver the helpful effects with fewer of the harmful ones.

In rodent studies, this has translated to real, documented advantages: SR-17018 produces robust analgesic effects with very little respiratory depression and much less analgesic tolerance than morphine. Substituting SR-17018 for morphine in dependent mice reversed analgesic tolerance and suppressed withdrawal symptoms, which is the mechanism that makes it interesting for human opioid discontinuation. This is the part that’s been gaining attention.

More recent research has shown SR-17018 also stimulates an unusual pattern of mu-opioid receptor phosphorylation that persists for hours, which may explain its tolerance-reversing effects through a mechanism distinct from the simpler G-protein bias model.

Important truths about it

It is still an opioid. It binds the mu-opioid receptor with a Ki of 11 nM, comparable to many clinical opioids. It produces opioid effects, and it can produce dependence.
It produces its own withdrawal. Studies have documented that SR-17018 causes withdrawal upon cessation, though shorter and reportedly less intense than morphine withdrawal. Long-term use will produce dependence on SR-17018.
It has not been studied in humans. All of the published data is from mice and rats. The drug has not been formally studied in humans, implying an unknown safety profile.
Reports of “minimal euphoria” are accurate but not the whole story. Most users describe SR-17018 as not producing the same kind of high other opioids do, which is part of why it’s used as a transition tool rather than recreationally. But the absence of euphoria doesn’t mean absence of opioid effects.

Preload, don’t quit cold first

The most important practical point: SR-17018 is taken alongside your existing 7-OH (or other opioid) for several days before you stop the original compound. This is called preloading and it’s how community protocols actually work. Stopping 7-OH first and then starting SR is the wrong sequence and leads to unnecessary withdrawal.

The reasoning: SR-17018’s tolerance-reversing and withdrawal-suppressing properties demonstrated in rodent studies work through substitution at the mu receptor, not as a withdrawal treatment after the fact. You want SR-17018 occupying receptors and shifting the receptor adaptation pattern while you taper or discontinue the original compound, not afterward.

Typical preload approach as reported in community discussion:

Continue your normal 7-OH dose
Add SR-17018 at a low starting dose, dosed every 6 to 8 hours
Stabilize on both for 2 to 3 days, ensuring SR is tolerated
Begin tapering or stopping the 7-OH while continuing SR-17018
Once the 7-OH is fully off and you’re stable on SR-17018 alone, begin tapering SR

This is significantly more comfortable than stopping 7-OH first and then trying to use SR to recover.

Dosing approaches reported in the community

There is no clinical dosing protocol for SR-17018 in humans. What follows are dose ranges reported on Reddit, Bluelight, and other community forums by people who have used it for opioid discontinuation. Treat these as starting reference points, not prescriptions.

Bluelight reports describe oral dosing starting with a small allergy-test dose (under 1 mg), followed by titration, with reports of doses around 10 mg producing minimal effects and 20 to 35 mg producing more noticeable effects in opioid-tolerant users. Community guides compiled from Reddit describe starting around 25 mg and finding a maintenance dose by tracking which 8-hour totals adequately managed withdrawal symptoms.

Common patterns:

Allergy test dose first. Under 10 mg orally, wait several hours, watch for any reaction.
Starting effective dose for opioid-dependent users: typically 50 to 150 mg orally, depending on dependence baseline.
Maintenance: total daily dose split across multiple administrations to account for SR-17018’s half-life of approximately 6 hours in rodent studies. Most protocols dose every 6 to 8 hours.
Taper: community guides describe reducing dose by approximately 10% per day once stabilized, with flexibility to pause and hold if withdrawal becomes intolerable.

Bioavailability: SR-17018 has approximately 69% oral bioavailability in mice and crosses the blood-brain barrier efficiently. It’s highly lipophilic with very poor water solubility, so dosing usually involves dissolution in a carrier (oils, propylene glycol, or ethanol) rather than aqueous suspension.

Important caveat: rodent doses don’t translate linearly to human doses. The 24 to 48 mg/kg/day used in mouse studies is not what humans should target. Community-reported human doses are much lower in absolute terms but the variability is significant and the data thin.

The community protocol

This is the most common SR-17018 plan reported by people in this community. It’s not a clinical protocol, it’s community experience. Treat it as a reference, not a prescription.

The standard plan:

Allergy test first. Take ~10 mg of SR-17018 orally. Wait several hours, watch for any reaction. SR isn’t a known allergen, but unregulated research chemicals can carry contaminants, so this step matters.
Day 1 — preload. SR-17018 50 mg, three times a day (every 6-8 hours), alongside your normal 7-OH dose. You’re not cutting 7-OH yet. You’re getting SR onto your receptors first.
Day 2 — cut 7-OH in half. Continue SR 50 mg x3. Reduce your 7-OH dose to half of normal.
Day 3 — drop 7-OH entirely. Continue SR 50 mg x3. No 7-OH at all from here on.
Days 3-10 — hold. Continue SR 50 mg x3. This is the stretch where SR is fully covering you and the 7-OH is out of your system.
Taper the SR. Toward the end of the 7-10 day window, step the SR down. A common taper: 50 mg x3 → 100 mg/day → 75 → 50 → 25 → jump. Adjust the pace to how you feel.

Key principles behind this protocol:

Use more SR, not 7-OH, to cover symptoms. If 50 mg x3 isn’t holding you in the first few days, the community approach is to increase the SR dose rather than reaching back for 7-OH. Some people report needing more than 50 mg per dose early on. The whole point is to break the 7-OH dependence, so don’t undermine it by topping up with 7-OH.
Keep the total SR course short. The strong community recommendation is 7-10 days of SR maximum. SR-17018 produces its own dependence and withdrawal with extended use. The longer you’re on it, the more you have to taper off of. Short course, then taper, then done.
Always taper the SR at the end. Don’t stop SR abruptly after a 7-10 day course. The step-down (100/75/50/25/jump or similar) reduces the chance of SR-related withdrawal symptoms. Abruptly stopping after even a short course can leave you with a rough few days that a simple taper would have prevented.

What the timeline looks like in practice: roughly 3 days of overlap/transition, 4-7 days of SR holding you while 7-OH clears and your receptors start adjusting, then a 2-4 day SR taper. Total: about 10-14 days start to finish.

If 50 mg x3 genuinely isn’t enough even after increasing, or if you’re coming off stacked synthetics rather than 7-OH alone, post in #sr17018 before improvising. Community experience there is ahead of anything published.

Dosing context and pharmacology

The protocol above is what this community commonly uses. For broader context: there is no clinical dosing protocol for SR-17018 in humans. Dose information comes entirely from community forums (Reddit, Bluelight) and user reports.

Bluelight reports describe oral dosing starting with a small allergy-test dose, followed by titration, with doses around 10 mg producing minimal effects and 20 to 35 mg producing more noticeable effects in opioid-tolerant users. Other community guides describe finding a maintenance dose by tracking which 8-hour totals adequately managed withdrawal symptoms. The community’s 50 mg x3 starting point sits within the range these sources describe.

Half-life and dosing frequency: SR-17018 has a half-life of approximately 6 hours in rodent studies. This is why the protocol doses every 6-8 hours, three times a day. Less frequent dosing lets blood levels drop and withdrawal symptoms break through between doses.

Bioavailability and how to take it: SR-17018 has roughly 69% oral bioavailability in mice and crosses the blood-brain barrier efficiently. It’s highly lipophilic with very poor water solubility, so it doesn’t mix into water. Dosing typically involves dissolving it in a carrier like oil, propylene glycol, or an ethanol-based solution. Vendors selling it in liquid form have usually done this already; powder requires you to handle it yourself.

The caveat on rodent data: the 24 to 48 mg/kg/day used in mouse studies does not translate linearly to human doses. Don’t do that math and dose accordingly; you’d massively overshoot. Community-reported human doses are far lower in absolute terms, and the variability between people is significant. The data is genuinely thin.

Does it work for MGM-15 and the other synthetics?

The short answer: probably yes for MGM-15, but the data is community-reasoned rather than research-confirmed.

The published Bohn lab research demonstrated SR-17018 substituting for and reversing tolerance to morphine and oxycodone in rodent models. There are no published studies specifically pairing SR-17018 with MGM-15, MIT-A, pseudo, or 7-OH.

That said, the pharmacological logic is consistent. MGM-15 is a semi-synthetic mu/delta agonist derived from 7-OH, and 7-OH itself is a potent mu-opioid agonist. SR-17018’s substitution mechanism operates at the mu receptor, which all of these compounds activate.

The MGM-15 caveat: MGM-15 has dual mu/delta activity, and SR-17018 is essentially mu-only (very low δ-receptor affinity, Ki >10,000 nM). SR covers the mu component but doesn’t replace the delta activation MGM-15 was producing. Expect a “delta gap” feeling (anhedonia, low mood, persistent off feeling), same as bupe users coming off MGM-15 report. Adjuncts and time help.

For pseudo or MIT-A, the same logic applies. Be honest about your full compound history when planning a transition. Stacked synthetics may need a more careful, possibly longer preload window than pure 7-OH.

The legal question (Federal Analogue Act)

SR-17018 is not specifically scheduled under the U.S. Controlled Substances Act or international drug control treaties. However, that doesn’t mean it’s clearly legal.

The Federal Analogue Act, 21 U.S.C. § 813, treats any substance “substantially similar” in chemical structure or pharmacological effect to a Schedule I or II controlled substance as if it were Schedule I, but only if intended for human consumption. SR-17018 is a mu-opioid receptor agonist with effects that overlap meaningfully with scheduled opioids, which means it could plausibly be prosecuted as a controlled substance analogue if intended for human consumption.

The practical reality:

Vendors sell SR-17018 as a “research chemical” with disclaimers that it’s not for human consumption. This labeling is the legal fig leaf the analogue act framework runs on.
Possession or use for personal harm-reduction purposes has not, to our knowledge, been the basis for federal prosecution. The analogue act has historically been used against vendors and large-scale distributors.
The legal landscape can change quickly. Designer opioids, including SR-17018’s structural cousin brorphine, are subject to ongoing regulatory attention.
State laws vary. Some states have broader analogue statutes than federal law.

This isn’t legal advice. If you’re concerned about your specific situation, consult a lawyer.

Sourcing and quality concerns

This is the genuinely hard part of using SR-17018, and worth being honest about.

No FDA oversight, no pharmaceutical-grade quality control. SR-17018 is currently available exclusively from chemical suppliers who are not adhering to standards usually applied to pharmaceuticals intended for human consumption.
Purity verification matters. Reputable RC suppliers provide third-party HPLC/NMR analysis. Less reputable ones provide nothing or fake certificates of analysis. Vet your source.
Contamination risk is real. Other novel synthetic opioids in the same chemical family (like brorphine) have appeared mislabeled or as adulterants. Brorphine specifically has potential for severe respiratory depression despite producing little euphoria, which is the failure mode you don’t want.
Dose verification is difficult. Without lab equipment, you’re trusting the vendor’s claimed concentration. Some users have reported significant batch-to-batch variability.

Naloxone reverses overdose from SR-17018 as it does for any mu-opioid agonist. Keep some on hand. This is non-negotiable.

Honest tradeoffs

In favor:

Genuinely novel pharmacology that may produce less respiratory depression and less tolerance than classical opioids in lab settings
Reported by users to have minimal euphoria, making it a tool rather than a temptation
Can substitute for stronger opioids and ease tolerance/withdrawal via the preload approach
Cash-pay, no prescriber needed (which is also a downside)

Against:

No human clinical data; all efficacy claims come from rodent studies
Sourcing is gray-market with all the quality concerns that brings
Legal status is ambiguous under the Analogue Act
It still produces dependence and withdrawal
Many users who get off their primary opioid using SR end up relapsing shortly after, with rapidly reduced tolerance creating significant overdose risk if they return to use

If you’re going to use it, plan the post-SR phase as carefully as the SR phase itself. PAWS, supplements, support, and structure for the weeks after stopping matter as much as the SR-17018 protocol itself.

When to seek emergency help

Severe respiratory depression (slow or shallow breathing, blue lips/fingertips)
Loss of consciousness
Severe chest pain or irregular heartbeat
Any thoughts of self-harm or suicide. Call or text 911/988.

Don’t use SR-17018 alone if at all possible.